期刊
EUROPEAN JOURNAL OF NEUROSCIENCE
卷 39, 期 3, 页码 485-500出版社
WILEY
DOI: 10.1111/ejn.12468
关键词
analgesia; cannabinoid; nociception; osteoarthritis; pain
资金
- Spanish 'Ministerio de Ciencia e Innovacion' [SAF2011-29864]
- 'Instituto de Salud Carlos III' (RETICS-Red de Trastornos Adictivos-Redes Tematicas de Investigacion Cooperativa en Salud) [RD06/0001/0001, RD06/0001/1004]
- Plan Nacional sobre Drogas (PNSD) [2009/026]
- Catalan Government [SGR2009-00131]
- ICREA Foundation (ICREA Academia)
Osteoarthritis is a degenerative joint disease associated with articular cartilage degradation. The major clinical outcome of osteoarthritis is a complex pain state that includes both nociceptive and neuropathic mechanisms. Currently, the therapeutic approaches for osteoarthritis are limited as no drugs are available to control the disease progression and the analgesic treatment has restricted efficacy. Increasing evidence from preclinical studies supports the interest of the endocannabinoid system as an emerging therapeutic target for osteoarthritis pain. Indeed, pharmacological studies have shown the anti-nociceptive effects of cannabinoids in different rodent models of osteoarthritis, and compelling evidence suggests an active participation of the endocannabinoid system in the pathophysiology of this disease. The ubiquitous distribution of cannabinoid receptors, together with the physiological role of the endocannabinoid system in the regulation of pain, inflammation and even joint function further support the therapeutic interest of cannabinoids for osteoarthritis. However, limited clinical evidence has been provided to support this therapeutic use of cannabinoids, despite the promising preclinical data. This review summarizes the promising results that have been recently obtained in support of the therapeutic value of cannabinoids for osteoarthritis management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据